中文版

Syncor International Corporation (NasdaqNM: SCOR) was founded in the United States in 1974. It pioneered the field of centralized compounding pharmacy by dispensing diagnostic and therapeutic radiopharmaceuticals. Syncor International Corporation then established 127 centralized radiopharmacies to supply radiopharmaceutical unit doses to about 7,000 medical institutions in the United States. Furthermore, in order to expand international markets, it established its wholly owned subsidiary - Syncor Overseas, Ltd.

Syncor Taiwan, Ltd. was founded in Taiwan in 1985 as the first centralized nuclear pharmacy outside the United States. Syncor Overseas, Ltd. gradually established 19 centralized Radiopharmacies to cover five continents. In late 2002, Cardinal Health Inc. (NYSE: CAH) acquired Syncor International Corporation.

Core members of the former Syncor Overseas, Ltd. established the Global Medical Solutions, Ltd. (GMS) in July 2003. At the same time, GMS purchased the Syncor Overseas, Ltd from the Cardinal Health, Inc. and immediately expanded its business projects and bases. In 2004, Syncor Taiwan, Ltd was renamed as Global Medical Solutions Taiwan, Ltd. (GMSTW). Since then, continuing efforts have been made to strengthen the management team, to improve equipment and facilities, to ensure quality of products, and to enhance service levels.

Since 1985, Syncor Ltd. Taiwan, the predecessor of GMSTW has actively participated in the development of nuclear medicine in Taiwan. Syncor Taiwan, Ltd. first introduced centralized compounding pharmacy from the United States and established centralized radiopharmacies in Northern, Central, and Southern parts of Taiwan to accomplish the following goals for a full range of unidose radiopharmaceutical services:
Since 1997, Syncor Taiwan, Ltd. has also cooperated with medical institutions throughout Taiwan via Build-Operation-Transfer business model to establish 14 nuclear medicine departments and imaging centers to provide economic, convenient and high quality radiopharmaceuticals to patients even in remote areas. Now all these highly invested capital equipment and facilities have been transferred to those institutions to provide high level medical services to their patients.

As Positron Emission Tomography (PET) technology rapidly flourished in last two decades, Syncor Taiwan Ltd. cooperated with Chung Shan Medical University Hospital in 1998 to establish the first PET/Cyclotron Center in Taiwan.

Due to the characteristic decay and instability properties of radiopharmaceuticals, the compounded medicinal preparations need to be delivered to their end-users in a timely fashion. Furthermore, GMSTW established a professional logistic service team for the distribution of radiopharmaceuticals in 2004. GMSTW now has carried more than 20 vehicles in service to cover all corners of Taiwan.

To ensure sustainable management, GMSTW strives “to enhance quality of personnel", "to ensure product quality", and "to improve service satisfaction":
  1. Enhancement of competence of personnel
    Enhancing quality of personnel is a prerequisite for the guarantee of the quality of our products. Over the years, GMSTW advances its elite employees from the company’s training programs. Currently, we have a team of prime quality. Among employees, 30% have postgraduate degrees while 26% possess graduate degrees.
    GMSTW retains 27 board certified pharmacists for compounding and dispensing practices. Among the employees, there are 10 certified senior radiation protection officers, 7 radiation safety officers and 35 with radiation safety license. It is noteworthy that through in-house training, 24 have been certified as Class I aseptic operators and 20 as Class II aseptic operators. For conveyance of radioactive materials there are 55 employees have certificates for transportation of dangerous goods.
  2. Warrant for product quality
    All radiopharmaceutical compounding practices are compliant with USP <797> Sterile Preparation Procedures. In addition, our PET drug practices conform the "Directions of PET Radioisotopes Compounding" regulations enforced by the Ministry of Health and Welfare.
    In 2006, GMSTW Taipei Pharmacy participated in the "Symbol of National Quality and National Biotechnology Medical Quality Award" competition and won the Bronze Medal, proving that our radiopharmacy practices satisfactorily met the national standards of quality.
  3. Improvement of service satisfaction
    To uphold GMS traditional business belief - "The Service Difference®" is to provide "Distinctive Service". In addition to improving customer service satisfaction, we conduct customer satisfaction survey on a regular basis to minimize drawbacks and to adjust service standards to meet customer’s demand.

For three decades, GMSTW has the honor to grow along with our nuclear medicine partners in Taiwan. We are at the forefront of constant innovation in nuclear medicine and a promising future awaits us. GMSTW will incessantly introduce new radiopharmaceuticals from global sources. We are now building a new PIC / S GMP compliant radiopharmaceutical manufacturing facility in Taichung and will soon be providing multiple dosage forms of radiopharmaceuticals of the international standard. Such establishment will effectively raise the overall level of radiopharmaceutical services to the medical community in Taiwan and fulfill the Corporate responsibility.

1985- Established first centralized compounding radio-pharmacy in Taiwan
1994- Established Kaohsiung compounding radio-pharmacy
1997- Established Taichung compounding radio-pharmacy
1997 ~2002- Built 14 imaging centers in Taiwan
1998- Established PET/Cyclotron Center
2003- Renamed as Global Medical Solutions Taiwan, Ltd.
2004- Established a nationwide logistics network for distribution of radiopharmaceuticals
2006- Awarded “National Symbol of Quality”
2009- Worked with local hospitals to overcome the crisis of global Tc-99m shortage
2010- All compounding radio-pharmacies were upgraded to meet the requirements in USP <797>”Pharmaceutical
    Compounding-Sterile Preparations
2010- F18 NaF approved by TFDA
2013- GMST provided F18 FCH for academic research and clinical trials
2014- F18 FLT approved by TFDA